Apoptosis inducer 7
Based on 1 publication(s) in Google Scholar
Apoptosis inducer 7 (Compound 5I) induces apoptosis in cancer cells. Apoptosis inducer 7 inducrs cleavage of PARP, caspases, down-regulation of anti-apoptotic protein c-Flip and up regulation of pro-apoptotic protein Noxa. Apoptosis inducer 7 exhibits antitumor activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2252278-57-0
- Formule: C49H68N2O7
- Masse moléculaire:797.07
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Apoptosis inducer 7
More
Activité biologique
Description
In Vitro
Apoptosis inducer 7 (Compound 5I) (0.098-50 μM, 96 hours; human tumor cell lines) exerts the most potent antitumor activities against human cancer cell lines[1].
Apoptosis inducer 7 (Compound 5I) induces apoptosis in HCT-116 cells, and the apoptosis induction is related to the downregulation of anti-apoptotic protein c-Flip and upregulation of pro-apoptotic protein Noxa[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human breast cancer MDA-MB-231 cells, human lung cancer A549 cells, human colorectal cancer HCT-116 cells, human liver cancer HepG-2 cells and one non-tumor human breast epithelial MCF-10A cells.
-
Concentration:0.098-50 μM
-
Incubation Time:96 hours
-
Result:Inhibited with IC50 values of 0.22, 0.15, 0.42, 0.14 and 1.03 μM for MDA-MB-231, A549, HCT-116, HepG-2 and MCF-10A, respectively.
-
Cell Line:HCT-116 cells
-
Concentration:0.5, 0.75 and 1.0 μM
-
Incubation Time:24 hours
-
Result:More than 40% of the cells were detected in the sub G1 phase.
-
Cell Line:HCT-116 cells
-
Concentration:0.5, 0.75 and 1.0 μM
-
Incubation Time:24 hours
-
Result:Induced cleavage of PARP, caspases and decreased the levels of c-Flip and HDAC3 proteins.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:KARPAS-422 subcutaneous xenograft in mice[1]
-
Dosage:5 mg/kg
-
Administration:Intraperitoneal injection; three times a week, for 14 days.
-
Result:Inhibited the tumor growth with an inhibition rate of 62.3%, without significant body weight loss.
Chemical Information
-
CAS No. 2252278-57-0
-
Masse moléculaire 797.07
-
Formule C49H68N2O7
-
SMILES
C[C@]12[C@@](C(C=C3[C@]2(CC[C@@]4([C@@]3([H])C[C@](C)(CC4)C(OCC5=CC=CC=C5)=O)C)C)=O)([H])[C@@]6([C@@](C(C)(C(/C(C6)=C/C(NC7CCN(CC7)C(OC(C)(C)C)=O)=O)=O)C)([H])CC1)C
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Bone Res
The HOXC10/NOD1/ERK axis drives osteolytic bone metastasis of pan-KRAS-mutant lung cancer. [Abstract]2024 Aug 27;12(1):47. PMID: 39191757
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Apoptosis inducer 7 Related Classifications
HY-149017 Related Classifications
Powered by Bioz